Wasatch Advisors Inc Esperion Therapeutics, Inc. Transaction History

Wasatch Advisors Inc

$19 Billion
Q1 2024

A detailed history of Wasatch Advisors Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 9,129,647 shares of ESPR stock, worth $19.1 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

9,129,647

Previous 8,891,103 2.68%

Holding current value

$19.1 Million

Previous $26.6 Million 7.96%

% of portfolio

0.13%

Previous 0.15%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$2.02 - $3.02 $481,858 - $720,402	238,544 Added 2.68%	9,129,647 $24.5 Million
Q4 2023 Feb 14, 2024	SELL	$0.73 - $3.08 $1.92 Million - $8.12 Million	-2,634,997 Reduced 22.86%	8,891,103 $26.6 Million
Q3 2023 Nov 14, 2023	SELL	$0.96 - $1.79 $1.55 Million - $2.89 Million	-1,613,456 Reduced 12.28%	11,526,100 $11.3 Million
Q2 2023 Aug 07, 2023	SELL	$1.2 - $1.76 $257,556 - $377,748	-214,630 Reduced 1.61%	13,139,556 $18.3 Million
Q1 2023 May 12, 2023	BUY	$1.46 - $7.3 $9.5 Million - $47.5 Million	6,505,808 Added 95.0%	13,354,186 $21.2 Million

Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $3.13 Million - $5.22 Million	-614,638 Reduced 8.24%	6,848,378 $42.7 Million
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $452,306 - $674,724	-82,992 Reduced 1.1%	7,463,016 $50 Million
Q2 2022 Aug 12, 2022	SELL	$4.77 - $6.67 $2.87 Million - $4.01 Million	-601,372 Reduced 7.38%	7,546,008 $48 Million
Q1 2022 May 13, 2022	BUY	$3.34 - $5.56 $5.88 Million - $9.79 Million	1,761,117 Added 27.58%	8,147,380 $37.8 Million
Q4 2021 Feb 15, 2022	BUY	$4.81 - $11.92 $15 Million - $37.1 Million	3,111,903 Added 95.04%	6,386,263 $31.9 Million
Q3 2021 Nov 12, 2021	SELL	$11.34 - $21.37 $5.59 Million - $10.5 Million	-492,575 Reduced 13.08%	3,274,360 $39.5 Million
Q2 2021 Aug 12, 2021	SELL	$19.4 - $28.71 $6.81 Million - $10.1 Million	-351,150 Reduced 8.53%	3,766,935 $79.7 Million
Q1 2021 May 10, 2021	BUY	$25.12 - $36.89 $3.02 Million - $4.43 Million	120,075 Added 3.0%	4,118,085 $116 Million
Q4 2020 Feb 12, 2021	BUY	$24.2 - $35.76 $38.4 Million - $56.8 Million	1,588,327 Added 65.91%	3,998,010 $104 Million
Q3 2020 Nov 10, 2020	BUY	$31.18 - $52.71 $36.3 Million - $61.4 Million	1,165,257 Added 93.64%	2,409,683 $89.6 Million
Q2 2020 Aug 12, 2020	BUY	$30.04 - $51.31 $10.2 Million - $17.3 Million	338,090 Added 37.3%	1,244,426 $63.9 Million
Q1 2020 May 08, 2020	BUY	$27.44 - $73.84 $6.63 Million - $17.8 Million	241,629 Added 36.35%	906,336 $28.6 Million
Q4 2019 Feb 13, 2020	BUY	$35.4 - $59.82 $1.21 Million - $2.05 Million	34,310 Added 5.44%	664,707 $39.6 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $275,001 - $379,194	-7,978 Reduced 1.25%	630,397 $23.1 Million
Q2 2019 Aug 07, 2019	BUY	$40.1 - $52.33 $23,498 - $30,665	586 Added 0.09%	638,375 $0
Q1 2019 May 08, 2019	BUY	$40.11 - $53.57 $3.01 Million - $4.03 Million	75,165 Added 13.36%	637,789 $0
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $197,489 - $315,588	5,339 Added 0.96%	562,624 $25.9 Million
Q3 2018 Nov 07, 2018	BUY	$40.74 - $51.41 $662,962 - $836,594	16,273 Added 3.01%	557,285 $0
Q2 2018 Aug 02, 2018	SELL	$36.2 - $76.4 $1.82 Million - $3.84 Million	-50,230 Reduced 8.5%	541,012 $0
Q1 2018 May 02, 2018	SELL	$65.94 - $80.76 $6.73 Million - $8.24 Million	-102,023 Reduced 14.72%	591,242 $0
Q4 2017 Jan 16, 2018	SELL	$43.47 - $67.43 $875,442 - $1.36 Million	-20,139 Reduced 2.82%	693,265 $0
Q3 2017 Nov 08, 2017	SELL	$43.8 - $52.77 $1.85 Million - $2.23 Million	-42,311 Reduced 5.6%	713,404 $0
Q2 2017 Aug 16, 2017	BUY	N/A	755,715	755,715 $0

Others Institutions Holding ESPR

# of Institutions

174

Shares Held

125M

Call Options Held

2.08M

Put Options Held

1.01M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $139M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wasatch Advisors Inc with notifications on news.

Account

Wasatch Advisors Inc Esperion Therapeutics, Inc. Transaction History